Analysts Anticipate Stryker Co. (SYK) Will Post Quarterly Sales of $3.32 Billion

Analysts expect that Stryker Co. (NYSE:SYK) will report sales of $3.32 billion for the current fiscal quarter, Zacks reports. Eleven analysts have issued estimates for Stryker’s earnings. The lowest sales estimate is $3.30 billion and the highest is $3.35 billion. Stryker posted sales of $3.01 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 10.3%. The company is scheduled to report its next quarterly earnings report on Thursday, July 26th.

On average, analysts expect that Stryker will report full year sales of $13.61 billion for the current financial year, with estimates ranging from $13.49 billion to $13.71 billion. For the next year, analysts forecast that the company will post sales of $14.47 billion per share, with estimates ranging from $14.34 billion to $14.58 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Stryker.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, April 26th. The medical technology company reported $1.68 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.60 by $0.08. The company had revenue of $3.24 billion for the quarter, compared to analyst estimates of $3.20 billion. Stryker had a net margin of 8.00% and a return on equity of 25.65%. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period last year, the business posted $1.48 earnings per share.

Several brokerages have recently issued reports on SYK. Zacks Investment Research raised shares of Stryker from a “sell” rating to a “hold” rating and set a $177.00 price objective for the company in a research report on Thursday, April 12th. Canaccord Genuity increased their price objective on shares of Stryker from $176.00 to $185.00 and gave the stock a “buy” rating in a research report on Friday, April 27th. Citigroup increased their price objective on shares of Stryker from $166.00 to $171.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 1st. ValuEngine raised shares of Stryker from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Finally, Morgan Stanley increased their price objective on shares of Stryker from $179.00 to $186.00 and gave the stock an “overweight” rating in a research report on Monday, February 26th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and fifteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $170.65.

SYK opened at $171.26 on Friday. The company has a current ratio of 1.64, a quick ratio of 1.08 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $62.87 billion, a price-to-earnings ratio of 26.39, a PEG ratio of 2.38 and a beta of 0.70. Stryker has a twelve month low of $167.97 and a twelve month high of $171.14.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 31st. Investors of record on Friday, June 29th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 1.10%. The ex-dividend date is Thursday, June 28th. Stryker’s dividend payout ratio (DPR) is currently 28.97%.

In other news, VP Yin C. Becker sold 23,221 shares of Stryker stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $165.96, for a total value of $3,853,757.16. Following the completion of the transaction, the vice president now owns 10,499 shares of the company’s stock, valued at approximately $1,742,414.04. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider David Floyd sold 55,119 shares of Stryker stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $166.58, for a total transaction of $9,181,723.02. The disclosure for this sale can be found here. In the last ninety days, insiders sold 134,200 shares of company stock valued at $22,151,180. 7.40% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. River Wealth Advisors LLC grew its position in shares of Stryker by 1.1% in the 1st quarter. River Wealth Advisors LLC now owns 29,300 shares of the medical technology company’s stock valued at $4,715,000 after acquiring an additional 309 shares during the period. Mogy Joel R Investment Counsel Inc. grew its position in shares of Stryker by 0.4% in the 1st quarter. Mogy Joel R Investment Counsel Inc. now owns 86,568 shares of the medical technology company’s stock valued at $13,931,000 after acquiring an additional 325 shares during the period. Advisor Partners LLC grew its position in shares of Stryker by 7.2% in the 4th quarter. Advisor Partners LLC now owns 4,827 shares of the medical technology company’s stock valued at $779,000 after acquiring an additional 326 shares during the period. Putnam FL Investment Management Co. grew its position in shares of Stryker by 0.7% in the 4th quarter. Putnam FL Investment Management Co. now owns 44,867 shares of the medical technology company’s stock valued at $6,947,000 after acquiring an additional 332 shares during the period. Finally, LS Investment Advisors LLC lifted its stake in shares of Stryker by 3.6% during the 4th quarter. LS Investment Advisors LLC now owns 10,249 shares of the medical technology company’s stock worth $1,587,000 after buying an additional 354 shares during the last quarter. 75.98% of the stock is owned by institutional investors.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Get a free copy of the Zacks research report on Stryker (SYK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit